Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testosterone supplementation in palliative hypogonadal male cancer patients
2025-522023-10-00Phase 2Authorised
- Sponsor
- Institut Jules Bordet
- Start
- Sep 2025
- Modality
- Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Sustanon 250 in androgen deficiency and cancer, sponsored by Institut Jules Bordet. Primary endpoints: Best improvement in independence (ADL scale) and Best improvement in symptoms (Edmonton Symptom Assessment Scale). Planned start Sep 2025; status: authorised.
02
Drugs
Sustanon 250
03
Conditions
androgen deficiencycancer
Beyond the preview
Go deeper on 2025-522023-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522023-10-00.